You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
-
2024
08-15
The KUNPENG Study of Vebreltinib's Phase II Results were Published in JCO
On July 27, 2024, the KUNPENG study, a multicenter, multi-cohort, open-label Phase II clinical study of Vebreltinib for patients with MET-abnormal advanced non-small cell lung cancer (NSCLC), led by Professor Yilong Wu’s team of Guangdong Provincial People's Hospital, was published in the internationally renowned journal Journal of Clinical Oncology (JCO, with an impact factor of IF = 42.1 in 2024). In this study, Vebreltinib has shown promising efficacy and a favorable safety profile inpatients with METex14-mutant NSCLC.
View Details
-
2022
09-28
Acceptance of Avistone's application for launch of MET inhibitor Vebreltinib enteric capsule (PLB-1001) in China
Avistone recently announced the application by its subsidiary Purun'ao Biotechnology for the launch of its Vebreltinib enteric capsule. The application has been accepted on September 24 by the National Medical Products Administration for priority review. The proposed application of Vebreltinib is for the treatment of partial late-stage or metastatic NSCLC patient with Mesenchymal-epithelial transition factor (MET) Exon 14 skipping.
View Details
-
2022
03-15
Bain Headline | Bain Capital Invests in Innovative Drug Company Avistone Pharmaceuticals to Help It Build Cancer Precision Treatment Platform
Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd ("Avistone") recently announced closure of Series A funding, raising over $200 million. Vivo Capital was the lead investor, while Bain Capital and Primavera were the co-investors. At the same time, Avistone acquired Beijing Pearl Biotechnology Co., Ltd., another company focusing on clinical trials, thus creating a research platform for various next-generation precision therapy target drugs.
View Details
